Research focus
About the research
What biomarkers and therapies can be developed for ALS?
Read the full research overview
Michael Benatar leads an active clinical and translational research program focused on biomarker and therapy development for ALS. He is the Executive Director of the ALS Center at the University of Miami. He is the PI of the ongoing Pre-Symptomatic Familial ALS study. He is also the PI of the CReATe Consortium, a rare diseases clinical research consortium focused on ALS and related neurodegenerative diseases.
Selected publications
3 listedTrial of Antisense Oligonucleotide Tofersen for SOD1 ALS
New England Journal of Medicine
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
The Lancet Neurology
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Neurotherapeutics
People & alumni
Team details haven’t been added. See the lab’s website for its current members.
Alumni details haven’t been added. Check the lab’s official website.
Sources & listing information
Find Research Labs maintains this page using public sources. The faculty member, lab, and university have not claimed or approved this listing. Listing a lab does not indicate endorsement, partnership, or a recruiting opportunity.
Request a correction or removal ↗ · About directory listings